- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
This study is for people with head and neck cancer that has come back or spread, and who have already tried a type of immune treatment. It compares a new drug, monalizumab, with a dummy treatment (placebo), both given with cetuximab, to see if it helps people live longer.
For: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint InhibitorGermany - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This study looks at a new drug, Monalizumab, combined with Cetuximab, for people with head and neck cancer that has come back or spread. It compares this combination to Cetuximab with a dummy drug (placebo) to see if it's safe and effective.
For: Squamous Cell Carcinoma of the Head and NeckUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)
This study is for adults with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to previous immune-boosting treatments. It's testing new combinations of medicines to see if they can help control the cancer, looking at how many people's cancer stops growing or shrinks after 12 weeks.
For: non small cell lung cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI)
This study is testing two new drugs, Monalizumab and MEDI5752 (also called volrustomig), for people with advanced cancer that has specific genetic features (MSI and/or dMMR). It's looking at how safe these drugs are and how well they shrink tumours.
For: cancerologyFrance